Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy

NAActive, not recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2025

Conditions
Narcolepsy Type 1HypersomniaSleep Disorder
Interventions
DEVICE

Dreem 3S recording

Subjects in both Arms A and B will undergo at-home recording with the Dreem 3S EEG Headband to assess sleep. Subjects will undergo in-lab polysomnography and multiple sleep latency testing while also wearing the Dreem 3S EEG headband system. Arm B participants will be asked to withdraw from some or all of their Narcolepsy related medication therapy for roughly 19 days in order to assess the ability of the Dreem Headband System in characterizing sleep disturbances related to Narcolepsy.

Trial Locations (4)

14623

Sleep Insights Medical Associates PLLC, Rochester

45245

Intrepid Research, Cincinnati

92335

Kaiser Permanente Fontana Medical Center, Fontana

94063

Stanford University, Redwood City

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Kaiser Permanente

OTHER

collaborator

Stanford University

OTHER

collaborator

Intrepid Research

UNKNOWN

collaborator

Sleep Insights

INDUSTRY

collaborator

Sleep Management Institute

UNKNOWN

lead

Beacon Biosignals

INDUSTRY

NCT06531876 - Efficacy of the Dreem 3S Ambulatory Sleep Monitoring Device for the Evaluation of Narcolepsy | Biotech Hunter | Biotech Hunter